Restari Picks Up AriBio’s PDE-5 Inhibitor In $230m Deal

Kidney, Liver Disease Focus

 
• By Jung Won Shin
  
Korea and US deal
AriBio Expanding Indications To Areas With High Unmet Needs Through New Restari Deal (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business